210 related articles for article (PubMed ID: 7548272)
1. Correction of deficient enzyme activity in a lysosomal storage disease, aspartylglucosaminuria, by enzyme replacement and retroviral gene transfer.
Enomaa N; Danos O; Peltonen L; Jalanko A
Hum Gene Ther; 1995 Jun; 6(6):723-31. PubMed ID: 7548272
[TBL] [Abstract][Full Text] [Related]
2. Adenovirus-mediated gene transfer results in decreased lysosomal storage in brain and total correction in liver of aspartylglucosaminuria (AGU) mouse.
Peltola M; Kyttälä A; Heinonen O; Rapola J; Paunio T; Revah F; Peltonen L; Jalanko A
Gene Ther; 1998 Oct; 5(10):1314-21. PubMed ID: 9930336
[TBL] [Abstract][Full Text] [Related]
3. Aspartylglycosaminuria: a review.
Arvio M; Mononen I
Orphanet J Rare Dis; 2016 Dec; 11(1):162. PubMed ID: 27906067
[TBL] [Abstract][Full Text] [Related]
4. Dissection of the molecular pathology of aspartylglucosaminuria provides the basis for DNA diagnostics and future therapeutic interventions.
Ikonen E; Syvänen AC; Peltonen L
Scand J Clin Lab Invest Suppl; 1993; 213():19-27. PubMed ID: 8322015
[TBL] [Abstract][Full Text] [Related]
5. A novel aspartylglucosaminuria mutation affects translocation of aspartylglucosaminidase.
Saarela J; von Schantz C; Peltonen L; Jalanko A
Hum Mutat; 2004 Oct; 24(4):350-1. PubMed ID: 15365992
[TBL] [Abstract][Full Text] [Related]
6. Correction of peripheral lysosomal accumulation in mice with aspartylglucosaminuria by bone marrow transplantation.
Laine M; Richter J; Fahlman C; Rapola J; Renlund M; Peltonen L; Karlsson S; Jalanko A
Exp Hematol; 1999 Sep; 27(9):1467-74. PubMed ID: 10480438
[TBL] [Abstract][Full Text] [Related]
7. Identification of a novel mutation causing aspartylglucosaminuria reveals a mutation hotspot region in the aspartylglucosaminidase gene.
Isoniemi A; Hietala M; Aula P; Jalanko A; Peltonen L
Hum Mutat; 1995; 5(4):318-26. PubMed ID: 7627186
[TBL] [Abstract][Full Text] [Related]
8. Use of nonviral promoters in adenovirus-mediated gene therapy: reduction of lysosomal storage in the aspartylglucosaminuria mouse.
Virta S; Rapola J; Jalanko A; Laine M
J Gene Med; 2006 Jun; 8(6):699-706. PubMed ID: 16518877
[TBL] [Abstract][Full Text] [Related]
9. Dissection of the molecular consequences of a double mutation causing a human lysosomal disease.
Riikonen A; Ikonen E; Sormunen R; Lehto VP; Peltonen L; Jalanko A
DNA Cell Biol; 1994 Mar; 13(3):257-64. PubMed ID: 8172656
[TBL] [Abstract][Full Text] [Related]
10. Mice with an aspartylglucosaminuria mutation similar to humans replicate the pathophysiology in patients.
Jalanko A; Tenhunen K; McKinney CE; LaMarca ME; Rapola J; Autti T; Joensuu R; Manninen T; Sipilä I; Ikonen S; Riekkinen P; Ginns EI; Peltonen L
Hum Mol Genet; 1998 Feb; 7(2):265-72. PubMed ID: 9425233
[TBL] [Abstract][Full Text] [Related]
11. Mutations causing aspartylglucosaminuria (AGU): a lysosomal accumulation disease.
Ikonen E; Peltonen L
Hum Mutat; 1992; 1(5):361-5. PubMed ID: 1301945
[TBL] [Abstract][Full Text] [Related]
12. Overgrowth of oral mucosa and facial skin, a novel feature of aspartylglucosaminuria.
Arvio P; Arvio M; Kero M; Pirinen S; Lukinmaa PL
J Med Genet; 1999 May; 36(5):398-404. PubMed ID: 10353787
[TBL] [Abstract][Full Text] [Related]
13. Aspartylglucosaminidase (AGA) is efficiently produced and endocytosed by glial cells: implication for the therapy of a lysosomal storage disorder.
Harkke S; Laine M; Jalanko A
J Gene Med; 2003 Jun; 5(6):472-82. PubMed ID: 12797112
[TBL] [Abstract][Full Text] [Related]
14. Expression of aspartylglucosaminidase in human tissues from normal individuals and aspartylglucosaminuria patients.
Enomaa NE; Lukinmaa PL; Ikonen EM; Waltimo JC; Palotie A; Paetau AE; Peltonen L
J Histochem Cytochem; 1993 Jul; 41(7):981-9. PubMed ID: 7685790
[TBL] [Abstract][Full Text] [Related]
15. Two novel mutations in a Canadian family with aspartylglucosaminuria and early outcome post bone marrow transplantation.
Laitinen A; Hietala M; Haworth JC; Schroeder ML; Seargeant LE; Greenberg CR; Aula P
Clin Genet; 1997 Mar; 51(3):174-8. PubMed ID: 9137882
[TBL] [Abstract][Full Text] [Related]
16. Amlexanox provides a potential therapy for nonsense mutations in the lysosomal storage disorder Aspartylglucosaminuria.
Banning A; Schiff M; Tikkanen R
Biochim Biophys Acta Mol Basis Dis; 2018 Mar; 1864(3):668-675. PubMed ID: 29247835
[TBL] [Abstract][Full Text] [Related]
17. Spectrum of mutations in aspartylglucosaminuria.
Ikonen E; Aula P; Grön K; Tollersrud O; Halila R; Manninen T; Syvänen AC; Peltonen L
Proc Natl Acad Sci U S A; 1991 Dec; 88(24):11222-6. PubMed ID: 1722323
[TBL] [Abstract][Full Text] [Related]
18. Aspartylglucosaminuria among Palestinian Arabs.
Zlotogora J; Ben-Neriah Z; Abu-Libdeh BY; Sury V; Zeigler M
J Inherit Metab Dis; 1997 Nov; 20(6):799-802. PubMed ID: 9427148
[TBL] [Abstract][Full Text] [Related]
19. Human leukocyte glycosylasparaginase: cell-to-cell transfer and properties in correction of aspartylglycosaminuria.
Dunder U; Mononen I
FEBS Lett; 2001 Jun; 499(1-2):77-81. PubMed ID: 11418116
[TBL] [Abstract][Full Text] [Related]
20. Functional Analysis of the Ser149/Thr149 Variants of Human Aspartylglucosaminidase and Optimization of the Coding Sequence for Protein Production.
Banning A; König JF; Gray SJ; Tikkanen R
Int J Mol Sci; 2017 Mar; 18(4):. PubMed ID: 28346360
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
